Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study by Girard, N., Galland-Girodet, S., Avrillon, V., Besse, B., Duruisseaux, M., Cadranel, J., Otto, J., Prevost, A., Roch, B., Bennouna, J., Bouledrak, K., Coudurier, M., Egenod, T., Lamy, R., Ricordel, C., Moro-Sibilot, D., Odier, L., Tillon-Strozyk, J., Zalcman, G., Missy, P., Westeel, V., Baldacci, S.

Get full text